Carvedilol Patent Expiration
Carvedilol is Used for reducing mortality associated with congestive heart failure. It was first introduced by Waylis Therapeutics Llc
Carvedilol Patents
Given below is the list of patents protecting Carvedilol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Coreg |
USRE40000 (Pediatric) | Method of treatment for decreasing mortality resulting from congestive heart failure |
Dec 07, 2015
(Expired) | Waylis Therap |
| Coreg | USRE40000 | Method of treatment for decreasing mortality resulting from congestive heart failure |
Jun 07, 2015
(Expired) | Waylis Therap |
Carvedilol's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Carvedilol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Efficacy Of Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis: A Randomized Controlled Trial | Dayanand Medical College and Hospital | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure | Mayo Clinic | NA |
TERMINATED
(Jun 1, 2026)
| PHASE2 |
| HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy | Washington University School of Medicine | NA |
TERMINATED
(May 1, 2026)
| PHASE2 |
| Cardioprotection in AML | University of Virginia | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |